Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Nov 6, 2019; 7(21): 3419-3435
Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3419
Table 3 Postoperative analysis of overall survival
Univariate analysis
Multivariate analysis
VariableHR (95%CI)P valueHR (95%CI)P value
Postoperative T stage< 0.0010.005
T1RefRef
T22.743 (1.054-7.139)2.210 (0.843-5.794)
T36.359 (2.759-14.657)2.730 (1.130-6.594)
T4a9.829 (4.345-22.235)3.847 (1.595-9.278)
Postoperative N stage< 0.001< 0.001
N0RefRef
N11.371 (0.820-2.290)0.962 (0.564-1.639)
N21.984 (1.250-3.151)1.251 (0.767-2.041)
N35.967 (4.109-8.663)2.659 (1.708-4.139)
Postoperative tumor size(cm)< 0.0010.022
< 5RefRef
≥ 52.938 (2.172-2.973)1.503 (1.060-2.132)
Lymphatic vascular infiltration (LVI)< 0.001< 0.001
NoRefRef
Yes3.185 (2.447-4.146)2.690 (2.036-3.554)
Postoperative blood transfusion< 0.0010.025
NoRefRef
Yes1.971 (1.402-2.771)1.505 (1.052-2.153)
General complications0.0010.028
NoRefRef
Yes1.784 (1.278-2.490)1.477 (1.042-2.093)
Digestive tract fistula0.125
NoRef
Yes2.001 (0.825-4.855)
Postoperative obstruction0.033
NoRef
Yes2.629 (1.083-6.386)
Incisional infection0.984
NoRef
Yes0.986 (0.245-3.966)
Abdominal infection0.964
NoRef
Yes1.021 (0.421-2.476)
Pulmonary infection0.001
NoRef
Yes2.104 (1.378-3.211)
Peritoneal lymphatic fistula0.565
NoRef
Yes1.297 (0.535-3.147)
intra-Abdominal hemorrhage0.093
NoRef
Yes2.136 (0.880-5.181)
Tumor involvement of the esophagus0.328
NoRef
Yes1.141 (0.876-1.487)
Neoadjuvant chemotherapy0.012
NoRef
Yes2.480 (1.225-5.022)
Adjuvant chemotherapy
NoRef
Yes1.166 (0.902-1.507)0.242
Lymph node ratio1.697 (0.998-2.867)0.053